22.418 articles found

Treatment with 1,2,3,4-tetrahydroisoquinolone affects the levels of nitric oxide, S-nitrosothiols, glutathione and the enzymatic activity of gamma-glutamyl transpeptidase in the dopaminergic structures of rat brain.

Lorenc-Koci E, Sokołowska M, Kwiecień I, Włodek L.

Brain Res · 2005-07-01

DOI: 10.1016/j.brainres.2005.04.039PMID: 15946655

A novel dopamine agonist for the transdermal treatment of Parkinson's disease.

Jenner P.

Neurology · 2005-07-01

DOI: 10.1212/wnl.65.2_suppl_1.s3PMID: 16030291

[Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].

Oberpichler-Schwenk H.

Med Monatsschr Pharm · 2005-07-01

PMID: 16038119

[Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].

Oberpichler-Schwenk H.

Med Monatsschr Pharm · 2005-07-01

PMID: 16038123

Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro.

Miyazaki I, Asanuma M, Diaz-Corrales FJ, Miyoshi K, Ogawa N.

Clin Neuropharmacol · 2005-07-01

DOI: 10.1097/01.wnf.0000175523.33334.24PMID: 16062092

Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study.

Linazasoro G, Lasa A, Van Blercom N.

Clin Neuropharmacol · 2005-07-01

DOI: 10.1097/01.wnf.0000172498.24770.54PMID: 16062096

[Systematic evaluation on clinical literature related with treatment of Parkinson's disease with traditional Chinese medicine].

Yang ZM, Tang XJ, Lao YR.

Zhongguo Zhong Xi Yi Jie He Za Zhi · 2005-07-01

PMID: 16089137

[Psychopharmacotherapy in somatic diseases -- treatment principles in daily medical routine].

Rothenhäusler HB, Kapfhammer HP.

Wien Med Wochenschr · 2005-07-01

DOI: 10.1007/s10354-005-0195-zPMID: 16092037

[Idiopathic Parkinson's disease: practical hints for the treatment].

Ludin HP.

Praxis (Bern 1994) · 2005-07-01

DOI: 10.1024/0369-8394.94.30.1147PMID: 16117469

Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's disease.

Riaz SS, Bradford HF.

Prog Neurobiol · 2005-07-01

DOI: 10.1016/j.pneurobio.2005.08.001PMID: 16256257

Levodopa treatment for patients in persistent vegetative or minimally conscious states.

Matsuda W, Komatsu Y, Yanaka K, Matsumura A.

Neuropsychol Rehabil · 2005-07-01

DOI: 10.1080/09602010443000588PMID: 16350982

Compositions and methods for the prevention or treatment of pain and other nervous system disorders

SPEICHER BRIAN T, KUCHARIK ROBERT F.

· 2005-06-30